The case for & against
Bull & Bear analysis
Bullish
Monogram Technologies, Inc. (NASDAQ: MNTX) specializes in advanced robotic surgical solutions, particularly in the orthopedic sector, focusing on knee replacements. The company is positioned at the forefront of the evolving orthopedic landscape, aiming to commercialize innovative and precise robotic technologies to address unmet needs within the market. Monogram intends to differentiate itself through its unique offering of fully autonomous surgical robots, highlighting a strategic approach towards capturing opportunities in a rapidly growing sector driven by demographic shifts and increasing preference for robotic-assisted surgeries.
Bull says
- ↑Q4 cash balance $15.7M, supplemented by $13M capital raise.
- ↑Submitted 510(k) application; FDA meeting expected in December.
- ↑$20B adult joint reconstruction market with 50% robotic knee target.
- ↑India partnership with Shelby hospital network speeds market entry.
- ↑Fully autonomous robotic focus differentiates from Stryker’s Mako.
- ↑High earnings yield, strong momentum, robust balance sheet quality.
Bear says
- ↓FDA requested additional details on 28k-page 510(k), risking delays.
- ↓Monthly cash burn ~$1.1–1.2M threatens liquidity if revenues lag.
- ↓India trial execution risks could postpone market launch.
- ↓Stryker holds 88% robotic knee share, intensifying competition.
- ↓Approval and trial timing beyond management control limits revenue.
- ↓Negative earnings yield and high short interest signal investor caution.
Earnings Call · Q2 2024 · Mgmt. Guidance
Updated 09-09-2026bullish
Transcript signals
Bull points
- we successfully submitted our 510K application to the FDA for our embossed TKA system on July 19th, and it has passed administrative review, moving into the primary substantial review phase expected to last approximately 60 days.
- are pretty confident with the application and the substantial equivalence of our system to the claims predicate, and we look forward to interacting with the FDA around that submission.
- we were able to announce our strategic clinical trial collaboration with Shalvi, one of the largest orthopedic hospital networks in the world, to work with six surgeons on a clinical trial targeting 102 patients with a three-month follow-up, which indicates a lot of strategic potential for post-approval launch.
Bear points
- Our average monthly cash burn, as we've stated in the past and we've stuck to, is a little over $1 million a month. We've been really tight on marshaling our resources to stay at that level, and we've succeeded in that goal.
Read full transcript analysis ›